For this purpose, we first evaluated the anti-IgM–induced BCR response in ibrutinib-naive cells from 30 CLL cases, all expressing CD49d above the established cutoff of 30% of positive cells (Table S1; Gattei et al., 2008). The gene discussed is CD40LG; the disease is B-cell chronic lymphocytic leukemia.